FDA Grants 2 Fast Track Designations to TT125-802 in EGFR/KRAS G12C NSCLC
TT125-802 monotherapy shrank the tumors in 5 of 7 patients with drug-resistant NSCLC, and no thrombocytopenia was observed.
Previous Post
Reaction and Significance of Fremanezumab’s Expanded Indication in Pediatric Migraine: Patricia Pozo-Rosich, MD, PhD
Next Post
Morning Headlines 8
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago